Payment overview · 2025
General Payments
$389.72
12 reported records · 6 companies
Healthcare provider profile · identity verified
Orlando Diaz, MD
Allopathic & Osteopathic Physicians|General Practice · PLANTATION, FL · NPI 1699104265
Verified facts
What the public records show
CMS Open Payments records show Orlando Diaz, MD received $389.72 in general payments during 2025 across 12 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 38.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $150.00 | 38.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $88.33 | 22.7% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $77.54 | 19.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.96 | 11.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.76 | 3.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.13 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $239.72 | 11 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $150.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $88.33 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $77.54 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $64.03 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.96 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 90 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 109 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
93 | 32 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 797 | 282 |
| Losartan Potassium | Losartan Potassium | 496 | 172 |
| Amlodipine Besylate | Amlodipine Besylate | 452 | 154 |
| Levothyroxine Sodium | Levothyroxine Sodium | 415 | 126 |
| Lisinopril | Lisinopril | 414 | 140 |
| Metformin Hcl | Metformin Hcl | 406 | 138 |
| Gabapentin | Gabapentin | 309 | 131 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 295 | 99 |
| Simvastatin | Simvastatin | 235 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 234 | 92 |
| Hydrochlorothiazide | Hydrochlorothiazide | 229 | 77 |
| Famotidine | Famotidine | 190 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 189 | 68 |
| Ezetimibe | Ezetimibe | 185 | 63 |
| Glipizide | Glipizide | 176 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 63 |
| Alendronate Sodium | Alendronate Sodium | 151 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 143 | 61 |
| Carvedilol | Carvedilol | 142 | 55 |
| Omeprazole | Omeprazole | 142 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 50 |
| Montelukast Sodium | Montelukast Sodium | 116 | 37 |
| Trazodone Hcl | Trazodone Hcl | 113 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 55 |
| Ozempic | Semaglutide | 109 | 29 |
| Azithromycin | Azithromycin | 107 | 86 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 51 |
| Chlorthalidone | Chlorthalidone | 98 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 36 |
| Glimepiride | Glimepiride | 97 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 30 |
| Eliquis | Apixaban | 93 | 32 |
| Jardiance | Empagliflozin | 90 | 30 |
| Memantine Hcl | Memantine Hcl | 90 | 32 |
| Farxiga | Dapagliflozin Propanediol | 89 | 29 |
| Prednisone | Prednisone | 89 | 50 |
| Doxycycline Hyclate | Doxycycline Hyclate | 88 | 76 |
| Clonidine Hcl | Clonidine Hcl | 83 | 26 |
| Torsemide | Torsemide | 80 | 29 |
| Metformin Hcl Er | Metformin Hcl | 77 | 27 |
| Glipizide Er | Glipizide | 75 | 24 |
| Irbesartan | Irbesartan | 75 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 33 |
| Furosemide | Furosemide | 71 | 32 |
| Finasteride | Finasteride | 67 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 22 |
| Donepezil Hcl | Donepezil Hcl | 64 | 28 |
| Atenolol | Atenolol | 62 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 21 |
| Methylprednisolone | Methylprednisolone | 61 | 51 |
| Spironolactone | Spironolactone | 61 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 25 |
| Ibuprofen | Ibuprofen | 57 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 21 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 56 | 15 |
| Baclofen | Baclofen | 55 | 29 |
| Januvia | Sitagliptin Phosphate | 55 | 23 |
| Nifedipine Er | Nifedipine | 55 | 20 |
| Mounjaro | Tirzepatide | 54 | 16 |
| Repatha Syringe | Evolocumab | 52 | 11 |
| Latanoprost | Latanoprost | 51 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 51 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 14 |
| Enalapril Maleate | Enalapril Maleate | 46 | 18 |
| Meloxicam | Meloxicam | 46 | 21 |
| Sertraline Hcl | Sertraline Hcl | 46 | 18 |
| Warfarin Sodium | Warfarin Sodium | 46 | 12 |
| Temazepam | Temazepam | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 31 |
| Meclizine Hcl | Meclizine Hcl | 43 | 25 |
| Sildenafil Citrate | Sildenafil Citrate | 43 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 31 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 40 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 22 |
| Allopurinol | Allopurinol | 38 | 12 |
| Folic Acid | Folic Acid | 38 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 12 |
| Trulicity | Dulaglutide | 37 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Ketoconazole | Ketoconazole | 35 | 20 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | 14 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | 16 |
| Novolog Flexpen | Insulin Aspart | 33 | 15 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | 13 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 30 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 16 |
| Hydrocortisone | Hydrocortisone | 29 | suppressed |
| Linzess | Linaclotide | 29 | 15 |
| Nabumetone | Nabumetone | 29 | 23 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | 11 |
| Sucralfate | Sucralfate | 28 | 17 |
| Cephalexin | Cephalexin | 27 | 24 |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Naproxen | Naproxen | 27 | 18 |
| Nystatin | Nystatin | 26 | 19 |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 23 |
| Clonazepam | Clonazepam | 25 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | 11 |
| Topiramate | Topiramate | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 22 |
| Terbinafine Hcl | Terbinafine Hcl | 24 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Ciclopirox | Ciclopirox | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 21 | 18 |
| Dilt-Xr | Diltiazem Hcl | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | 14 |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Benzonatate | Benzonatate | 16 | 14 |
| Cilostazol | Cilostazol | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $389.72 · 12 records | SANOFI-AVENTIS U.S. LLC | ABRYSVO, COMIRNATY, Cologuard Collection Kit, JARDIANCE, Ozempic, PREVNAR 20, Rybelsus, TRELEGY ELLIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error